+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance



Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance



Liver Transplantation 19(9): 937-944



Recipients of liver transplantation (LT) may develop immunological tolerance. Factors predictive of tolerance are not clearly understood. Transplant recipients with normal liver function tests and without active viral hepatitis or autoimmune disease who presented with side effects of immunosuppression or a high risk of de novo malignancies were selected to participate in this prospective study. Twenty-four patients fulfilled the inclusion criteria and, therefore, underwent a gradual reduction of immunosuppression. Tolerance was defined as normal liver function tests after immunosuppression withdrawal. Basal clinical and immunological characteristics, including lymphocyte counts and subpopulations (T, B, natural killer, CD4(+) , CD8(+) , and regulatory T cells) and the phytohemagglutinin stimulation index (SI), were compared for tolerant and nontolerant patients. Fifteen of the 24 patients (62.5%) were tolerant at a median of 14 months (interquartile range = 8.5-22.5 months) after complete immunosuppression withdrawal. Tolerant patients had a longer median interval between transplantation and inclusion in the study (156 for tolerant patients versus 71 months for nontolerant patients, P = 0.003) and a lower median SI (7.49 for tolerant patients versus 41.73 for nontolerant patients, P = 0.01). We identified 3 groups of patients with different probabilities of tolerance: in the first group (n = 7 for an interval > 10 years and an SI < 20), 100% reached tolerance; in the second group (n = 10 for an interval > 10 years and an SI > 20 or an interval < 10 years and an SI < 20), 60% reached tolerance; and in the third group (n = 7 for an interval < 10 years and an SI > 20), 29% reached tolerance. In conclusion, a high proportion of select LT recipients can reach tolerance over the long term. Two simple basal variables-the time from transplantation and the SI-may help to identify these patients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036941923

Download citation: RISBibTeXText

PMID: 23784747

DOI: 10.1002/lt.23686


Related references

Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. Journal of Hepatology 44(4): 702-709, 2006

Sustained and complete weaning from immunosuppression is feasible in liver transplant recipients with recurrent hepatitis C Safety and medium-term outcome. Hepatology 36(4 Part 2): 186A, 2002

Acute cellular rejection in liver transplant recipients under cyclosporine immunosuppression: predictive factors of response to antirejection therapy. Transplantation 73(12): 1936-1943, 2002

Weaning of immunosuppression in liver transplant recipients. Transplantation 63(2): 243-249, 1997

Outcomes after complete immunosuppression withdrawal in liver transplant recipients: rejection-free graft tolerance or late acute rejection?. Canadian Journal of Gastroenterology 12(6): 387-389, 1998

Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 72(3): 449-454, 2001

Weaning of immunosuppression in long-term liver transplant recipients. Transplantation 59(2): 212-217, 1995

Ribavirin treatment facilitates weaning from immunosuppression in liver transplant recipients with recurrent hepatitis C. Journal of Hepatology 38(Suppl. 2): 43, 2003

Risks and benefits of weaning immunosuppression in liver transplant recipients: long-term follow-up. Transplantation Proceedings 29(1-2): 1174-1177, 1997

Complete withdrawal of immunosuppression in liver transplant recipients with recurrent hepatitis C Safety and short-term outcome. Gastroenterology 122(4 Suppl 1): A 633, 2002

Approaching operational tolerance in long-term pediatric liver transplant recipients receiving minimal immunosuppression. Transplantation Proceedings 29(1-2): 449-451, 1997

Monitoring the patient off immunosuppression. Conceptual framework for a proposed tolerance assay study in liver transplant recipients. Transplantation 72(8 Suppl): S13-S22, 2001

A randomised controlled trial of total immunosuppression withdrawal in stable liver transplant recipients. Gut 56(2): 304-306, 2007

Posttransplant metabolic syndrome in the withdrawal of immunosuppression in Pediatric Liver Transplant Recipients (WISP-R) pilot trial. American Journal of Transplantation 15(3): 779-785, 2015

Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid. Transplantation 83(12): 1571-1576, 2007